丰富的环境通过减少老年男性APP/PS1小鼠的微细胞补充信号来缓解AD的病态进展
Hai-Chao Chen1, Jia-Xin Cao1, Yi-Shu Zhang1
1Institute of Anatomy and Histology & Embryology, Neuroscience, School of Basic Medical Sciences, Lanzhou University, Lanzhou, Gansu, People's Republic of China.
概括
通过减少炎症和保持神经元连接,丰富的环境可以改善记忆,并减少老鼠的阿尔茨海默病 (AD) 病理. 这表明环境丰富可以减缓阿尔茨海默病的进展.
科学领域:
- 神经科学
- 老年学
- 病理学
背景情况:
- 阿尔茨海默病 (AD) 涉及遗传因素和环境因素.
- 之前的研究表明,丰富的环境有利于AD小鼠,但机制尚不清楚.
研究的目的:
- 在老年APP/PS1小鼠中研究丰富环境对AD病理和认知的影响.
- 阐明丰富环境影响阿尔茨海默病进展的机制.
主要方法:
- 使用过时的APP/PS1转基因小鼠和野生类型的 littermates.
- 将小鼠置于标准 (SE) 或增强 (EE) 环境中5个月.
- 评估认知功能,粉样β (Aβ) 和酸化tau (p-Tau) 聚合,微质炎症标志物 (Tlr-4,NF-κB,iNOS),C1q表达和树突脊柱完整性.
主要成果:
- 丰富的环境保留了APP/PS1小鼠的认知功能.
- 降低了Aβ和p- Tau的聚合,以及微质炎症.
- EE降低了C1q表达,并减缓了海马体的树突性脊柱损失.
结论:
- 丰富的环境可以缓解阿尔茨海默病的进展.
- 机制包括调节微质炎症和维持神经元完整性,特别是海马树突.
相关概念视频
01:26Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
01:22Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260